145094 - Allergic rhinoconjunctivitis. Allergen-specific immunotherapy options in Australia
- : Online
This free online learning module provides 15 clinical questions and immediate answers about an original peer-reviewed article written for GPs.Relevance to General Practice
Allergen-specific immunotherapy (AIT) has traditionally been reserved for patients with moderate-to-severe allergic rhinoconjunctivitis refractory to maximal pharmacotherapy.
However, evidence is mounting that AIT should be considered not just a symptom-control measure but also a curative tool that may alter the course of allergic disease.
Although specialist assessment is required to initiate AIT, GP familiarity with its administration, risks and benefits is crucial to maximising patient safety and satisfaction.